Tilray Brands, Inc. (TLRY)
USD 0.49
(-0.12%)
USD 0.49
(-0.12%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | 223.35 Million USD | 51.98% |
| 2023 | 146.96 Million USD | 25.8% |
| 2022 | 116.81 Million USD | -5.17% |
| 2021 | 123.18 Million USD | -10.53% |
| 2020 | 137.68 Million CAD | 146.99% |
| 2019 | 55.74 Million CAD | 126.05% |
| 2018 | 24.65 Million CAD | 92.06% |
| 2017 | 12.83 Million CAD | 180.16% |
| 2016 | 4.58 Million CAD | 3799.28% |
| 2015 | -123.88 Thousand CAD | 0.0% |
| 2014 | - CAD | 0.0% |
| 2013 | - CAD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 FY | 138.59 Million USD | -5.69% |
| 2024 Q1 | 44.19 Million USD | -34.2% |
| 2024 Q2 | 47.4 Million USD | 7.27% |
| 2024 Q3 | 27.83 Million USD | -41.28% |
| 2024 Q4 | 63.29 Million USD | 127.38% |
| 2023 Q4 | 67.16 Million USD | 674.09% |
| 2023 Q3 | -11.69 Million USD | -129.16% |
| 2023 FY | 146.96 Million USD | 25.8% |
| 2023 Q1 | 48.61 Million USD | 822.03% |
| 2023 Q2 | 40.12 Million USD | -17.46% |
| 2022 Q3 | 39.82 Million USD | 21.56% |
| 2022 Q4 | -6.73 Million USD | -116.9% |
| 2022 FY | 116.81 Million USD | -5.17% |
| 2022 Q2 | 32.76 Million USD | -35.7% |
| 2022 Q1 | 50.95 Million USD | 126.49% |
| 2021 Q4 | 22.49 Million USD | -9.53% |
| 2021 Q1 | 56.77 Million CAD | 66.19% |
| 2021 Q2 | 30.41 Million CAD | -46.43% |
| 2021 Q3 | 24.86 Million CAD | -18.23% |
| 2021 FY | 123.18 Million USD | -10.53% |
| 2020 Q3 | 44.05 Million CAD | 49.59% |
| 2020 FY | 137.68 Million CAD | 146.99% |
| 2020 Q1 | 33.98 Million CAD | 23.28% |
| 2020 Q4 | 34.16 Million CAD | -22.45% |
| 2020 Q2 | 29.45 Million CAD | -13.34% |
| 2019 Q3 | 13.15 Million CAD | 191.95% |
| 2019 Q2 | 4.5 Million CAD | -53.84% |
| 2019 Q1 | 9.76 Million CAD | 229.93% |
| 2019 FY | 55.74 Million CAD | 126.05% |
| 2019 Q4 | 27.56 Million CAD | 109.55% |
| 2018 Q1 | 3.06 Million CAD | -21.47% |
| 2018 Q3 | 6.7 Million CAD | 39.2% |
| 2018 Q4 | 2.95 Million CAD | -55.89% |
| 2018 FY | 24.65 Million CAD | 92.06% |
| 2018 Q2 | 4.81 Million CAD | 57.21% |
| 2017 Q3 | 2.7 Million CAD | -11.81% |
| 2017 Q4 | 3.9 Million CAD | 44.31% |
| 2017 FY | 12.83 Million CAD | 180.16% |
| 2017 Q1 | 2.88 Million CAD | 67.35% |
| 2017 Q2 | 3.06 Million CAD | 6.16% |
| 2016 Q1 | 512.43 Thousand CAD | 140.18% |
| 2016 FY | 4.58 Million CAD | 3799.28% |
| 2016 Q4 | 1.72 Million CAD | 24.23% |
| 2016 Q3 | 1.38 Million CAD | 41.93% |
| 2016 Q2 | 979.16 Thousand CAD | 91.08% |
| 2015 Q2 | - CAD | 0.0% |
| 2015 Q1 | - CAD | 0.0% |
| 2015 FY | -123.88 Thousand CAD | 0.0% |
| 2015 Q4 | 213.35 Thousand CAD | 177.09% |
| 2015 Q3 | -276.75 Thousand CAD | 0.0% |
| 2014 Q1 | - CAD | 0.0% |
| 2014 Q3 | - CAD | 0.0% |
| 2014 Q4 | - CAD | 0.0% |
| 2014 FY | - CAD | 0.0% |
| 2014 Q2 | - CAD | 0.0% |
| 2013 FY | - CAD | 0.0% |
| 2013 Q2 | - CAD | 0.0% |
| 2013 Q3 | - CAD | 0.0% |
| 2013 Q4 | - CAD | 0.0% |
| 2013 Q1 | - CAD | 0.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| 2012 Q4 | - CAD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 326.16 Million USD | 31.523% |
| Embecta Corp. | 749.9 Million USD | 70.216% |
| ANI Pharmaceuticals, Inc. | 305.3 Million USD | 26.843% |
| Dynavax Technologies Corporation | 182.11 Million USD | -22.641% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | -205.68% |
| Pacira BioSciences, Inc. | 490.3 Million USD | 54.447% |
| PainReform Ltd. | -15 Thousand USD | 1489106.667% |
| Aquestive Therapeutics, Inc. | 29.75 Million USD | -650.709% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -2578.336% |
| SCYNEXIS, Inc. | 124.51 Million USD | -79.374% |
| China SXT Pharmaceuticals, Inc. | 553.97 Thousand USD | -40218.176% |
| Cosmos Health Inc. | 4.34 Million USD | -5035.015% |
| Journey Medical Corporation | 52.52 Million USD | -325.26% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -2578.336% |
| Safety Shot Inc | -74.45 Thousand USD | 300073.139% |
| Alpha Teknova, Inc. | 10.29 Million USD | -2069.299% |
| Intra-Cellular Therapies, Inc. | 430.62 Million USD | 48.133% |
| Bright Green Corporation | -237.01 Thousand USD | 94334.566% |
| Procaps Group, S.A. | 239.56 Million USD | 6.77% |
| Theratechnologies Inc. | 62.12 Million USD | -259.496% |
| Harrow Health, Inc. | 90.55 Million USD | -146.652% |
| Sonoma Pharmaceuticals, Inc. | 4.74 Million USD | -4607.081% |
| Biofrontera Inc. | 16.62 Million USD | -1243.303% |
| DURECT Corporation | 6.83 Million USD | -3169.668% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 57.355% |
| Cronos Group Inc. | 6.99 Million USD | -3094.884% |
| OptiNose, Inc. | 62.35 Million USD | -258.198% |
| Ironwood Pharmaceuticals, Inc. | 441.16 Million USD | 49.372% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 73813.201% |
| RedHill Biopharma Ltd. | 3.05 Million USD | -7212.978% |
| Organogenesis Holdings Inc. | 309.79 Million USD | 27.902% |
| Guardion Health Sciences, Inc. | 5.39 Million USD | -4040.334% |
| Cumberland Pharmaceuticals Inc. | 33.48 Million USD | -567.0% |
| Radius Health, Inc. | 307.71 Million USD | 27.415% |
| Universe Pharmaceuticals INC | 10.07 Million USD | -2116.25% |
| ProPhase Labs, Inc. | 16.23 Million USD | -1275.399% |
| Phibro Animal Health Corporation | 312.48 Million USD | 28.525% |
| Procaps Group S.A. | 239.56 Million USD | 6.77% |
| Alvotech | -69.42 Million USD | 421.729% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -17054.455% |
| Viatris Inc. | 6.43 Billion USD | 96.531% |
| Rockwell Medical, Inc. | 8.7 Million USD | -2466.073% |
| Aytu BioPharma, Inc. | 54.58 Million USD | -309.173% |
| SIGA Technologies, Inc. | 122.09 Million USD | -82.936% |
| Lifecore Biomedical, Inc. | 41.85 Million USD | -433.694% |
| Shineco, Inc. | 882.16 Thousand USD | -25218.42% |
| PetIQ, Inc. | 252.74 Million USD | 11.628% |
| Regencell Bioscience Holdings Limited | -745.58 Thousand USD | 30056.357% |
| Incannex Healthcare Limited | 12 Thousand USD | -1861158.333% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 87.91% |
| Alimera Sciences, Inc. | 61.17 Million USD | -265.132% |
| Silver Spike Investment Corp. | 8.1 Million USD | -2656.535% |
| Assertio Holdings, Inc. | 125.04 Million USD | -78.611% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6811.00 USD | 3279368.83% |
| Petros Pharmaceuticals, Inc. | 4.19 Million USD | -5229.087% |
| Clever Leaves Holdings Inc. | 6.55 Million USD | -3306.818% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 9367.0% |
| Avadel Pharmaceuticals plc | 27.11 Million USD | -723.657% |
| Hempacco Co., Inc. | -1.21 Million USD | 18470.204% |
| Talphera, Inc. | -4.89 Million USD | 4662.84% |
| Alvotech | -69.42 Million USD | 421.729% |
| Eagle Pharmaceuticals, Inc. | 221.67 Million USD | -0.757% |
| Lantheus Holdings, Inc. | 709.54 Million USD | 68.522% |
| Currenc Group, Inc. | 17.35 Million USD | -1186.858% |
| Kamada Ltd. | 52.59 Million USD | -324.68% |
| Indivior PLC | 907 Million USD | 75.375% |
| Evoke Pharma, Inc. | 4.97 Million USD | -4386.085% |
| Flora Growth Corp. | 17.73 Million USD | -1159.167% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 9367.0% |
| Evolus, Inc. | 140.52 Million USD | -58.939% |
| HUTCHMED (China) Limited | 453.55 Million USD | 50.755% |
| Amphastar Pharmaceuticals, Inc. | 343.96 Million USD | 35.066% |
| Akanda Corp. | 111.44 Thousand USD | -200306.464% |